Liberty One Investment Management LLC Buys 1,685 Shares of Eli Lilly and Company $LLY

Key Points

• Liberty One Investment Management LLC increased its stake in Eli Lilly and Company by 4.7%, acquiring an additional 1,685 shares, bringing its total holdings to 37,454 shares, valued at approximately $29.2 million.
• Eli Lilly reported strong quarterly earnings, with an EPS of $6.31, exceeding analyst expectations, and a revenue of $15.56 billion, marking a 37.6% year-over-year increase.
• Analysts have mixed ratings for Eli Lilly, with several maintaining a 'buy' rating and price targets ranging from $800 to $1,023, while the consensus target price stands at $938.61.

Liberty One Investment Management LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,454 shares of the company's stock after buying an additional 1,685 shares during the quarter. Eli Lilly and Company comprises 3.0% of Liberty One Investment Management LLC's portfolio, making the stock its 12th largest holding. Liberty One Investment Management LLC's holdings in Eli Lilly and Company were worth $29,196,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth about $27,000. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $40,000. Finally, TD Capital Management LLC lifted its position in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $808.88 on Tuesday. The company has a market cap of $765.57 billion, a price-to-earnings ratio of 52.87, a P/E/G ratio of 1.15 and a beta of 0.47. The business's fifty day simple moving average is $756.56 and its two-hundred day simple moving average is $766.20. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's revenue for the quarter was up 37.6% on a year-over-year basis. During the same period last year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on LLY shares. HSBC boosted their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Erste Group Bank raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Tuesday, October 14th. UBS Group reduced their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Morgan Stanley decreased their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a research note on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $938.61.

Insiders Place Their Bets

In other news, Director Jamere Jackson bought 200 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.